Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Segment Information (Details)

v3.25.3
Schedule of Segment Information (Details) - USD ($)
12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Research and development:    
Clinical $ 5,632,217 $ 2,613,188
Non-clinical 2,260,300 3,888,787
Other [1] 462,787 (764,723)
Total research and development 8,355,304 5,737,252
General and administrative:    
Payroll and related 1,716,552 715,846
Professional fees 3,695,790 1,922,292
Consulting 1,314,698 1,532,601
Other [2] 1,761,771 1,960,106
Total general and administrative 8,488,811 6,130,845
Total operating expenses $ 16,844,115 $ 11,868,097
[1] Other research and development consists primarily of payroll and related expenses and dues, licenses and subscriptions. The balance is negative for the year ended September 30, 2024 due to the cancellation of accrued but unpaid bonuses that had been awarded for fiscal years 2022 and 2023.
[2] Other general and administrative consists primarily of facilities, insurance, filing fees, travel expenses and franchise taxes.